Journals / Haydarpaşa Numune Medical Journal / 2018 / Cilt: 58 - Sayı: 4

Serum Lipoprotein(a) and Lipid Levels in Patients with Chronic Plaque-Type Psoriasis

Pages
210–213
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion and Conclusion: According to the results of our study, increased Lp(a) levels in patients with psoriasis may be more likely to induce atherosclerosis than those in the normal population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Psoriasis vulgaris (PV) was considered to be a chronic, recurrent skin disease, but it has been accepted as a chronic systemic inflammatory disease in recent years.
📊
Key Findings & Data:Lipoprotein(a) (Lp(a)) is a lipoprotein that is synthesized in the liver and has a low-density lipoprotein (LDL)-like molecular structure consisting of phospholipids, cholesterol, and apolipoprotein B-100 derivative.
💡
Conclusion & Impact:Discussion and Conclusion: According to the results of our study, increased Lp(a) levels in patients with psoriasis may be more likely to induce atherosclerosis than those in the normal population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Introduction: Psoriasis vulgaris (PV) was considered to be a chronic, recurrent skin disease, but it has been accepted as a chronic systemic inflammatory disease in recent years. Lipoprotein(a) (Lp(a)) is a lipoprotein that is synthesized in the liver and has a low-density lipoprotein (LDL)-like molecular structure consisting of phospholipids, cholesterol, and apolipoprotein B-100 derivative. Serum levels of Lp(a) are not affected by the amount of lipid incorporated into the diet and lifestyle changes. The aim of this study is to compare blood lipid and Lp(a) levels between the PV patient group and healthy control group and to investigate whether psoriasis creates a predisposition to atherosclerosis. Methods: Forty-four patients with clinical and/or histopathological diagnosis of chronic plaque-type PV and 48 healthy subjects were included in the study. Serum total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, serum LDL cholesterol, very low-density lipoprotein (VLDL) cholesterol, and serum Lp(a) levels were measured. Results: Total cholesterol, triglyceride, and HDL, LDL, and VLDL cholesterol levels were not statistically different between the psoriasis and healthy control groups (p=0.071, p=0.374, p=0.060, p=0.421, and p=0.759, respectively). Lp(a) levels were higher in the psoriasis group than in the healthy control group (p<0.001). Discussion and Conclusion: According to the results of our study, increased Lp(a) levels in patients with psoriasis may be more likely to induce atherosclerosis than those in the normal population. On the other hand, the identification of the Lp(a) level in patients with psoriasis with cardiovascular diseases may be an appropriate diagnostic tool for the evaluation of atherosclerotic and vasoocclusive pathologies.

🔖

Cite This Article

KAYIRAN, M. A., DERVİŞ, E. (2018). Serum Lipoprotein(a) and Lipid Levels in Patients with Chronic Plaque-Type Psoriasis. Haydarpaşa Numune Medical Journal, Cilt: 58 - Sayı: 4, 210–213. https://ajindex.com/articles/197348

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kalkan G. Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management. Turkderm- Turk Arch Dermatol Venereology 2017
  2. 71–7. [CrossRef ] 2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM
  3. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013
  4. 377–85. [CrossRef ] 3. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995
  5. 982–6. [CrossRef ] 4. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978
  6. 469–75. [CrossRef ] 5. Vanizor Kural B, Orem A, Cimşit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003
  7. 71–82. [CrossRef] 6. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985
  8. 199–205. 7. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome-scientific evidence and therapeutic implications. J Med Life 2014
  9. 468–71. 8. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol 2017
  10. e8. 9. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010
  11. 181–3. [CrossRef ] 10. Mancia G, Bombelli M, Facchetti R, Casati A, Ronchi I, et al. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. J Hypertens 2010
  12. 999–1006. [CrossRef ] 11. Homma Y. Predictors of atherosclerosis. J Atheroscler Thromb 2004
  13. 265–70. [CrossRef ] 12. Deb A, Caplice NM. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 2004
  14. 258–64. [CrossRef ] 13. Aasvee K, Kurvinen E, Jordania R, Jauhiainen M, Sundvall J. Lipoprotein parameters in relation to other risk factors of atherosclerosis in adults and newborns: Tallinn Young Family Study. Scand J Clin Lab Invest 2004
  15. 245–53. [CrossRef ] 14. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008
  16. 5–21. [CrossRef ] 15. Choi WJ, Park EJ, Kwon IH, Kim KH, Kim KJ. Association b